Brain Advance Access originally published online on January 13, 2005
Brain 2005 128(2):239-249; doi:10.1093/brain/awh391
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brain Vol. 128 No. 2 © Guarantors of Brain 2005; all rights reserved
Cholinergic systems in progressive supranuclear palsy
Institute for Ageing and Health, University of Newcastle upon Tyne, UK
Correspondence to: Dr Naomi M. Warren, Clinical Research Fellow in Neurology, Wolfson Research Centre, Institute for Ageing and Health, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE4 6BE, UK E-mail: n.m.warren{at}ncl.ac.uk
Progressive supranuclear palsy (PSP) is a progressive neurodegenerative disease characterized by akinetic-rigid features, falls, a supranuclear gaze palsy and subcortical dementia. Pathologically, there is abnormal accumulation of tau protein. Cholinergic deficits are thought to underlie the postural instability and cognitive impairment of PSP, but trials of cholinergic agonists and cholinesterase inhibitors have failed to show improvement in motor function, quality of life and cognitive impairment. The five cortico-basal ganglia loops, linking functionally related areas of the brain, are damaged in PSP, leading to specific clinical deficits. Cholinergic dysfunction is related to loss of cholinergic interneurons in the striatum, compounded by reduced inputs into the circuits from other cholinergic nuclei, such as the pedunculopontine nucleus and nucleus basalis of Meynert. Normal cholinergic transmission requires the presence of intact cholinergic neurons capable of releasing sufficient acetylcholine, and functional muscarinic and nicotinic receptors. Whilst there is evidence from autopsy and in vivo studies of loss of cholinergic neurons in PSP, the receptor status is unknown. This may be critical to understanding the basis for the poor therapeutic response to cholinomimetics. Symptomatic treatment using cholinergic drugs may thus be improved by more specific targeting of cholinergic receptors or nuclei. There is also evidence that cholinergic agents may have disease-modifying effects. This article reviews the key clinical features of PSP, along with normal basal ganglia anatomy and cholinergic transmission. Cholinergic deficits based on clinical and neurochemical parameters are then discussed, before concluding with suggested future directions for cholinergic treatments.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Zampieri and R. P Di Fabio Balance and Eye Movement Training to Improve Gait in People With Progressive Supranuclear Palsy: Quasi-Randomized Clinical Trial Physical Therapy, December 1, 2008; 88(12): 1460 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vale Current Management of the Cognitive Dysfunction in Parkinson's Disease: How Far Have We Come? Experimental Biology and Medicine, August 1, 2008; 233(8): 941 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Schmeichel, L. C. Buchhalter, P. A. Low, J. E. Parisi, B. W. Boeve, P. Sandroni, and E. E. Benarroch Mesopontine cholinergic neuron involvement in Lewy body dementia and multiple system atrophy Neurology, January 29, 2008; 70(5): 368 - 373. [Abstract] [Full Text] [PDF]
|
|